“As these end markets continue to recover, we'll get back to that high single-digit growth over time.”

In context

“table as we look ahead? I know it's January '26, but as we look ahead to future years, what is the path there? What do you need to see to believe that that's on the table next? Rainer Blair: Well, I mean, would say it's too early to comment on 2027 and beyond. To the point you just made. Here's how we're thinking about it. I mean, fundamentally, our businesses are in excellent end markets. Those growth drivers that we've talked about are very much intact. We expect those growth drivers to continue to recover here. What are some of those? Well, the proliferation of biologics, some of the advancements that we see in life science research, and then, of course, the diagnostics area, bringing those diagnostics much closer to the patient. So, we don't see any change to our long-term framework. As these end markets continue to recover, we'll get back to that high single-digit growth over time. Patrick Donnelly: Understood. Thank you, guys. Rainer Blair: Gotcha. Operator: Thank you. We will move next with Dan Leonard with UBS. Please go ahead. Your line is open. Dan Leonard: Hi, Dan. Thank you very much for taking the question. You've talked a couple of times about the importance of an improving biotech funding environment on your life sciences business. Can you remind us how sensitive would the biotech business segment be to an improvement in biotech funding? Rainer Blair: So that emerging biotech sector for us is traditionally been in the sort of 15% of the business overall. It's probably a little bit better. Yeah. Probably more like 5% of overall, Danaher, or 15% of bioprocess and 10, 15%. So, I mean, it's not it it's there is some level of exposure, but it's not the majority”